Other research analysts also recently issued research reports about the stock. Morgan Stanley upgraded shares of Phibro Animal Health from an underweight rating to an equal rating and boosted their price objective for the stock from $21.00 to $30.00 in a report on Thursday, September 5th. They noted that the move was a valuation call. ValuEngine upgraded shares of Phibro Animal Health from a sell rating to a hold rating in a research report on Wednesday, October 2nd. Credit Suisse Group reiterated a neutral rating and set a $25.00 target price (down from $31.00) on shares of Phibro Animal Health in a research report on Wednesday, August 28th. Barclays decreased their target price on shares of Phibro Animal Health from $25.00 to $18.00 and set an underweight rating on the stock in a research report on Thursday, August 29th. Finally, TheStreet lowered shares of Phibro Animal Health from a b- rating to a c+ rating in a research report on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $26.60.
Shares of NASDAQ:PAHC traded down $0.62 on Friday, hitting $23.95. 96,591 shares of the company were exchanged, compared to its average volume of 171,597. The company’s 50 day moving average price is $23.66 and its two-hundred day moving average price is $26.22. Phibro Animal Health has a one year low of $20.00 and a one year high of $36.98. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.77 and a current ratio of 3.21. The firm has a market capitalization of $985.64 million, a price-to-earnings ratio of 18.46, a PEG ratio of 6.91 and a beta of 0.82.
Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.05). Phibro Animal Health had a return on equity of 25.52% and a net margin of 4.99%. The company had revenue of $190.00 million for the quarter, compared to the consensus estimate of $199.22 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The business’s revenue for the quarter was down 5.0% compared to the same quarter last year. Research analysts predict that Phibro Animal Health will post 1.1 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be given a dividend of $0.12 per share. The ex-dividend date is Tuesday, November 26th. This represents a $0.48 annualized dividend and a dividend yield of 2.00%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 31.37%.
Several institutional investors have recently modified their holdings of PAHC. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Phibro Animal Health by 74.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,361 shares of the company’s stock valued at $29,000 after acquiring an additional 581 shares in the last quarter. State of Tennessee Treasury Department boosted its position in Phibro Animal Health by 11.0% in the third quarter. State of Tennessee Treasury Department now owns 8,860 shares of the company’s stock valued at $189,000 after buying an additional 876 shares in the last quarter. Marshall Wace North America L.P. boosted its position in Phibro Animal Health by 12.4% in the second quarter. Marshall Wace North America L.P. now owns 7,119 shares of the company’s stock valued at $226,000 after buying an additional 786 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its position in Phibro Animal Health by 3,930.5% in the second quarter. Oppenheimer Asset Management Inc. now owns 7,537 shares of the company’s stock valued at $240,000 after buying an additional 7,350 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new position in Phibro Animal Health in the second quarter valued at about $261,000. Institutional investors and hedge funds own 49.94% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
See Also: Quiet Period Expirations
Receive News & Ratings for Phibro Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Phibro Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.